Torsades de pointes associated with fluoroquinolones: Importance of concomitant risk factors

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 242-247

  Amankwa, Kwadwo ^a   Krishnan, Subramaniam C ^a   Tisdale, James E ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TORSADE DES POINTES; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; CARDIOVASCULAR DISEASES; FEMALE; FLUOROQUINOLONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OFLOXACIN; OSTEOMYELITIS; RISK FACTORS; TORSADES DE POINTES;

EID: 1542316304     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.11.376     Document Type: Article

References (29)

1. Bednar M.M., Harrigan E.P., Anziano R.J., Camm A.J., Ruskin J.N. The QT interval. Prog Cardiovasc Dis. 43:2001;1-45.
2. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 354:1999;1625-1633.
3. Glassman A.H., Bigger J.T. Jr. Antipsychotic drugs prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 158:2001;1774-1782.
4. Owens R.C. Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and Torsades de pointes. Pharmacotherapy. 21:2001;301-319.
5. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 21:2001;1468-1472.
6. Satoh Y., Sugiyama A., Chiba K., Tamura K., Hashimoto K. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. J Cardiovasc Pharmacol. 36:2000;510-515.
7. Iannini P.B., Circiumaru I. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy. 21:2001;361-362.
8. Bertino J.S. Jr, Owens R.C. Jr, Carnes T.D., Iannini P.B. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis. 34:2002;861-863.
9. Demolis J.L., Kubitza D., Tenneze L., Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 68:2000;658-666.
10. Noel G.J., Natarajan J., Chien S., Hunt T.L., Goodman D.B., Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 73:2003;292-303.
11. McCaig L.F., Besser R.E., Hughes J.M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis. 9:2003;432-437.
12. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382.
13. Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 105:2002;1943-1948.
14. Harris L., Downar E., Shaikh N.A., Chen T. Antiarrhythmic potential of chloroquine new use for an old drug. Can J Cardiol. 4:1988;295-300.
15. Sanchez-Chapula J.A., Salinas-Stefanon E., Torres-Jacome J., Benavides-Haro D.E., Navarro-Polanco R.A. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther. 297:2001;437-445.
16. Demaziere J., Fourcade J.M., Busseuil C.T., Adeleine P., Meyer S.M., Saissy J.M. The hazards of chloroquine self prescription in west Africa. J Toxicol Clin Toxicol. 33:1995;369-370.
17. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30:1981;239-245.
18. Rodvold K.A., Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy. 21:(Suppl):2001;233S-252S.
19. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
20. Levaquin (levofloxacin) [package insert]. Raritan (NJ): Ortho-McNeil Pharmaceutical; 2003
21. Nakashima M., Uematsu T., Kosuge K., Kusajima H., Ooie T., Masuda Y., et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 39:1995;2635-2640.
22. Adamantidis M.M., Dumotier B.M., Caron J.F., Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol. 12:1998;70-76.
23. Hagiwara T., Satoh S., Kasai Y., Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol. 87:2001;231-234.
24. Samaha F. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. [letter] Am J Med. 107:1999;528-529.
25. Iannini P.B., Doddamani S., Byazovra E., Circiumaru I., Kramer H. Risk of torsades de pointes with non-cardiac drugs. [letter] BMJ. 322:2001;46-47.
26. Iannini P.B. Quinolone-induced QT interval prolongation a not-so-unexpected class effect. [letter] J Antimicrob Chemother. 47:2001;893.
27. Curtis L.H., Ostbye T., Sendersky V., et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 114:2003;135-141.
28. Zeltser D., Justo D., Halkin A., Prokhorov V., Heller K., Viskin S. Torsades de pointes due to noncardiac drugs. Most patients have easily identifiable risk factors. Medicine. 82:2003;282-290.
29. Viskin S., Justo D., Halkin A., Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 45:2003;415-427.